Two-year clinical outcomes of Taiwanese and other Asian ethnicities with atrial fibrillation treated with edoxaban in the ETNA-AF Asia registry

IF 2.2 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS
Chun-Chieh Wang, Cheng-I Cheng, Kwo-Chang Ueng, Wei-Shiang Lin, Tze-Fan Chao, Lian-Yu Lin, Chien-Lung Huang, Kuan-Cheng Chang, Guang-Yuan Mar, Yu-Cheng Hsieh, Martin Unverdorben, Cathy Chen
{"title":"Two-year clinical outcomes of Taiwanese and other Asian ethnicities with atrial fibrillation treated with edoxaban in the ETNA-AF Asia registry","authors":"Chun-Chieh Wang,&nbsp;Cheng-I Cheng,&nbsp;Kwo-Chang Ueng,&nbsp;Wei-Shiang Lin,&nbsp;Tze-Fan Chao,&nbsp;Lian-Yu Lin,&nbsp;Chien-Lung Huang,&nbsp;Kuan-Cheng Chang,&nbsp;Guang-Yuan Mar,&nbsp;Yu-Cheng Hsieh,&nbsp;Martin Unverdorben,&nbsp;Cathy Chen","doi":"10.1002/joa3.13212","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>The non-vitamin K oral anticoagulant (NOAC), edoxaban, is approved for stroke prevention in patients with atrial fibrillation (AF) in many Asian countries. Nonetheless, data on its long-term effectiveness and safety in routine clinical practice are limited in Taiwan.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>The Global ETNA-AF (Edoxaban Treatment in routiNe clinical prActice) registry is an observational study that integrates data of AF patients receiving edoxaban from multiple regional registries. Here, we report the subgroup analysis of two-year outcomes in Taiwan (<i>N</i> = 973) and three Asian countries (South Korea, Hong Kong, Thailand; <i>N</i> = 2326).</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Compared with other Asian ethnicities, edoxaban users in Taiwan were older and had lower creatinine clearance levels. The incidence of clinical events was low and comparable in four Asian countries. Upon 2 years of observation, the annualized rates of cardiovascular death and ischemic stroke/systemic embolic event were 0.50% and 0.90% in Taiwan and 0.33% and 0.91% in other Asian ethnicities, respectively. The annualized rates of major/clinically relevant non-major bleeding and major gastrointestinal bleeding were 2.06% and 0.39% in Taiwan and 2.06% and 0.49% in other Asian ethnicities, respectively. Intracranial hemorrhage was rarely reported in four Asian countries (annualized rate: 0.35%).</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Although some differences in patient characteristics were observed among Asian ethnicities, the low clinical event rates in two-year ETNA-AF data reassure the effectiveness and safety of edoxaban in routine care for AF patients in Taiwan, South Korea, Hong Kong, and Thailand.</p>\n </section>\n </div>","PeriodicalId":15174,"journal":{"name":"Journal of Arrhythmia","volume":"41 1","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11730714/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Arrhythmia","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/joa3.13212","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Background

The non-vitamin K oral anticoagulant (NOAC), edoxaban, is approved for stroke prevention in patients with atrial fibrillation (AF) in many Asian countries. Nonetheless, data on its long-term effectiveness and safety in routine clinical practice are limited in Taiwan.

Methods

The Global ETNA-AF (Edoxaban Treatment in routiNe clinical prActice) registry is an observational study that integrates data of AF patients receiving edoxaban from multiple regional registries. Here, we report the subgroup analysis of two-year outcomes in Taiwan (N = 973) and three Asian countries (South Korea, Hong Kong, Thailand; N = 2326).

Results

Compared with other Asian ethnicities, edoxaban users in Taiwan were older and had lower creatinine clearance levels. The incidence of clinical events was low and comparable in four Asian countries. Upon 2 years of observation, the annualized rates of cardiovascular death and ischemic stroke/systemic embolic event were 0.50% and 0.90% in Taiwan and 0.33% and 0.91% in other Asian ethnicities, respectively. The annualized rates of major/clinically relevant non-major bleeding and major gastrointestinal bleeding were 2.06% and 0.39% in Taiwan and 2.06% and 0.49% in other Asian ethnicities, respectively. Intracranial hemorrhage was rarely reported in four Asian countries (annualized rate: 0.35%).

Conclusions

Although some differences in patient characteristics were observed among Asian ethnicities, the low clinical event rates in two-year ETNA-AF data reassure the effectiveness and safety of edoxaban in routine care for AF patients in Taiwan, South Korea, Hong Kong, and Thailand.

Abstract Image

在ETNA-AF亚洲注册中心,台湾和其他亚洲种族心房颤动患者接受依多沙班治疗的两年临床结果
背景:非维生素K口服抗凝剂(NOAC)依多沙班在许多亚洲国家被批准用于房颤(AF)患者的卒中预防。然而,台湾常规临床实践中关于其长期有效性和安全性的数据有限。方法:全球ETNA-AF(依多沙班在常规临床实践中的治疗)登记是一项观察性研究,整合了来自多个地区登记的接受依多沙班治疗的房颤患者的数据。结果:与其他亚洲种族相比,台湾依多沙班使用者年龄较大,肌酐清除率较低。4个亚洲国家的临床事件发生率较低且具有可比性。经过2年的观察,心血管死亡和缺血性卒中/全身性栓塞事件的年化率在台湾分别为0.50%和0.90%,在其他亚洲种族分别为0.33%和0.91%。台湾地区的重大/临床相关的非重大出血和重大胃肠道出血的年化率分别为2.06%和0.39%,其他亚洲种族的年化率分别为2.06%和0.49%。颅内出血在四个亚洲国家很少报道(年化率:0.35%)。结论:尽管在亚洲种族中观察到患者特征的一些差异,但在2年ETNA-AF数据中较低的临床事件发生率保证了依多沙班在台湾、韩国、香港和泰国房颤患者常规护理中的有效性和安全性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Arrhythmia
Journal of Arrhythmia CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
2.90
自引率
10.00%
发文量
127
审稿时长
45 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信